ES2564010T3 - Composición farmacéutica para tratar o prevenir el glaucoma - Google Patents

Composición farmacéutica para tratar o prevenir el glaucoma Download PDF

Info

Publication number
ES2564010T3
ES2564010T3 ES10758728.9T ES10758728T ES2564010T3 ES 2564010 T3 ES2564010 T3 ES 2564010T3 ES 10758728 T ES10758728 T ES 10758728T ES 2564010 T3 ES2564010 T3 ES 2564010T3
Authority
ES
Spain
Prior art keywords
group
halogen
alkyl
alkoxy
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10758728.9T
Other languages
English (en)
Inventor
Masahiko Hagihara
Kenji Yoneda
Eiji Okanari
Manabu Shigetomi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ube Corp
Original Assignee
Ube Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ube Industries Ltd filed Critical Ube Industries Ltd
Application granted granted Critical
Publication of ES2564010T3 publication Critical patent/ES2564010T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/83—Thioacids; Thioesters; Thioamides; Thioimides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una solución oftálmica médica a ser utilizada en el tratamiento o profilaxis de glaucoma que comprende un compuesto de ácido piridilaminoacético representado por la fórmula (1): **Fórmula** en donde cada uno de R1, R2 y R3 representa en forma independiente un átomo de hidrógeno o un grupo alquilo C1- C6, Y representa un grupo anular heteroaromático bicíclico o un grupo Q1-Q2, cada uno de los cuales puede encontrarse sustituido por uno o más grupos seleccionados del grupo que consiste en un átomo halógeno, un grupo alquilo C1-C6, un grupo alquilo C1-C6 halógeno, un grupo alcoxilo C1-C6, un grupo alcoxilo C1-C6 halógeno y un grupo alquiltio C1-C6, en donde Q1 representa un grupo arileno o un grupo heteroarileno de 5 a 6 miembros, Q2 representa un grupo aromático o un grupo heterocíclico anular de 5 a 6 miembros, cada uno de los que puede encontrarse sustituido por uno o más grupos seleccionados del grupo que consiste en un átomo halógeno, un grupo hidroxilo, un grupo alquilo C1-C6, un grupo alquilo C1-C6 halógeno, un grupo alcoxilo C1-C6 y un grupo alcoxilo C1-C6 halógeno, Z representa un grupo aromático o un grupo anular heteroaromático de 5 a 6 miembros, cada uno de los que puede encontrarse sustituido por uno o más grupos seleccionados del grupo que consiste en un átomo halógeno, un grupo alquilo C1-C6, un grupo alquilo C1-C6 halógeno, un grupo alcoxilo C1-C6 y un grupo alcoxilo C1-C6 halógeno, o una sal farmacéuticamente aceptable de estos como ingrediente eficaz, y en donde la solución se coloca en el ojo.
ES10758728.9T 2009-03-30 2010-03-30 Composición farmacéutica para tratar o prevenir el glaucoma Active ES2564010T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009082725 2009-03-30
JP2009082725 2009-03-30
PCT/JP2010/055719 WO2010113957A1 (ja) 2009-03-30 2010-03-30 緑内障の治療又は予防のための医薬組成物

Publications (1)

Publication Number Publication Date
ES2564010T3 true ES2564010T3 (es) 2016-03-17

Family

ID=42828246

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10758728.9T Active ES2564010T3 (es) 2009-03-30 2010-03-30 Composición farmacéutica para tratar o prevenir el glaucoma

Country Status (17)

Country Link
US (1) US8685986B2 (es)
EP (1) EP2415763B1 (es)
JP (2) JP5300033B2 (es)
KR (1) KR101681347B1 (es)
CN (1) CN102448940B (es)
AU (1) AU2010231630B2 (es)
CA (1) CA2757291C (es)
CY (1) CY1117193T1 (es)
DK (1) DK2415763T3 (es)
ES (1) ES2564010T3 (es)
HR (1) HRP20160104T1 (es)
HU (1) HUE026742T2 (es)
PL (1) PL2415763T3 (es)
PT (1) PT2415763E (es)
SI (1) SI2415763T1 (es)
SM (1) SMT201600055B (es)
WO (1) WO2010113957A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20190509T1 (hr) * 2008-03-12 2019-05-03 Ube Industries, Ltd. Spoj piridilaminooctene kiseline
PT2415763E (pt) 2009-03-30 2016-03-30 Ube Industries Composição farmacêutica para tratamento ou prevenção do glaucoma
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
CA2773998A1 (en) * 2009-09-11 2011-03-17 Ube Industries, Ltd. Substituted carbonyl compound
KR20120101722A (ko) 2009-12-25 2012-09-14 우베 고산 가부시키가이샤 아미노피리딘 화합물
KR102074020B1 (ko) * 2012-07-13 2020-02-05 산텐 세이야꾸 가부시키가이샤 술폰아미드 화합물의 조합
US9339496B2 (en) 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
BR112015024743A2 (pt) 2013-03-28 2017-07-18 Ube Industries composto de biarila substituída
MX385505B (es) 2014-01-10 2025-03-18 Santen Pharmaceutical Co Ltd Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico
KR101824829B1 (ko) * 2014-01-10 2018-02-01 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물을 포함하는 의약 제제
KR102111157B1 (ko) * 2014-01-10 2020-05-14 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
EP3156395B1 (en) * 2014-06-10 2019-01-09 UBE Industries, Ltd. Method for producing heteroaromatic sulfonamide compound
CN106458904B (zh) * 2014-06-10 2021-12-03 宇部兴产株式会社 N-取代磺酰胺化合物及其制造方法
US10774072B2 (en) 2014-06-10 2020-09-15 Ube Industries, Ltd. Crystal of N-substituted sulfonamide compound
JP2017206445A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 呼吸器疾患の治療及び／又は予防のための医薬組成物
JP6872322B2 (ja) * 2015-07-01 2021-05-19 参天製薬株式会社 クエン酸エステルを含有するデポ剤
TWI794140B (zh) * 2015-07-09 2023-03-01 日商參天製藥股份有限公司 含有吡啶基胺基乙酸化合物之預防及/或治療劑
EP3689349A4 (en) 2017-09-29 2021-06-23 Santen Pharmaceutical Co., Ltd. MEDICINAL PRODUCT CONTAINING A COMPOUND OF PYRIDYLAMINOACETIC ACID
KR20200103041A (ko) 2017-12-21 2020-09-01 산텐 세이야꾸 가부시키가이샤 오미데네팍의 조합
EP3730138B1 (en) 2017-12-21 2024-02-14 Santen Pharmaceutical Co., Ltd. Combination of sepetaprost and ripasudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
US11666563B2 (en) * 2017-12-28 2023-06-06 Santen Pharmaceutical Co., Ltd. Pharmaceutical preparation containing pyridyl aminoacetic acid compound
KR20220089106A (ko) 2020-12-21 2022-06-28 이성규 도르졸라마이드 또는 폴리소르베이트80을 유효성분으로 포함하는 점안용 조성물
CN118084895B (zh) * 2024-02-28 2025-09-05 中国药科大学 一种一氧化氮供体型Omidenepag衍生物及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
YU47600A (sh) 1998-01-27 2002-09-19 Aventis Pharmaceuticals Products Inc. SUPSTITUISANI OKSOAZAHETEROCIKLIL INHIBITORI FAKTORA Xa
AU2001290250A1 (en) 2000-09-21 2002-04-02 Ono Pharmaceutical Co. Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
MXPA04001253A (es) 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
JP2005507413A (ja) 2001-10-26 2005-03-17 アラーガン　インコーポレイテッド ＥＰ２−受容体作用薬としてのω−シクロアルキル１７−ヘテロアリールプロスタグランジンＥ２類似物
PY0300568A (es) 2002-01-31 2004-10-01 Pfizer Prod Inc Metabolitos del acido(3-{[4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi)acetico
AU2003211574A1 (en) 2002-03-05 2003-09-16 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
US20070000939A1 (en) 2002-10-29 2007-01-04 Vasilios Vasiadis Device for handling and orientating pills or tablets in a precise manner
AU2004216898A1 (en) 2003-03-04 2004-09-16 Pfizer Products Inc. Use of EP2 selective receptor agonists in medical treatment
GB0329620D0 (en) 2003-12-22 2004-01-28 Pharmagene Lab Ltd EP2 receptor agonists
WO2005072743A1 (ja) 2004-01-30 2005-08-11 Ono Pharmaceutical Co., Ltd. 気管支拡張剤
JP2007186424A (ja) 2004-11-26 2007-07-26 Ono Pharmaceut Co Ltd 気管支拡張剤
ES2564804T3 (es) 2004-02-12 2016-03-29 Mitsubishi Tanabe Pharma Corporation Compuesto de indazol y uso farmacéutico del mismo
EP1593671A1 (en) 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
US20060135773A1 (en) * 2004-06-17 2006-06-22 Semple Joseph E Trisubstituted nitrogen modulators of tyrosine phosphatases
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
ES2346685T3 (es) 2005-01-14 2010-10-19 F. Hoffmann-La Roche Ag Deribados de tiazol-4-carboxamida como antagonistas de mglur5.
WO2006106711A1 (ja) 2005-03-30 2006-10-12 Eisai R & D Management Co., Ltd. ピリジン誘導体を含有する抗真菌剤
EP1912957A4 (en) 2005-08-03 2009-05-13 Merck Frosst Canada Ltd EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS
CA2618486A1 (en) 2005-08-09 2007-02-15 Asterand Uk Limited Ep2 receptor agonists
US7696235B2 (en) 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
AU2007280130B2 (en) 2006-07-28 2011-09-22 Pfizer Products Inc. EP2 agonists
FI123744B (fi) * 2006-09-06 2013-10-15 Sandvik Mining & Constr Oy Menetelmä kallion poraamiseksi
HRP20190509T1 (hr) 2008-03-12 2019-05-03 Ube Industries, Ltd. Spoj piridilaminooctene kiseline
PT2415763E (pt) 2009-03-30 2016-03-30 Ube Industries Composição farmacêutica para tratamento ou prevenção do glaucoma

Also Published As

Publication number Publication date
US20120190852A1 (en) 2012-07-26
HRP20160104T1 (hr) 2016-03-25
HK1170490A1 (zh) 2013-03-01
PT2415763E (pt) 2016-03-30
KR20120003475A (ko) 2012-01-10
EP2415763B1 (en) 2016-01-27
JPWO2010113957A1 (ja) 2012-10-11
EP2415763A1 (en) 2012-02-08
JP2013151548A (ja) 2013-08-08
CA2757291C (en) 2017-05-23
SI2415763T1 (sl) 2016-05-31
DK2415763T3 (en) 2016-03-07
WO2010113957A1 (ja) 2010-10-07
US8685986B2 (en) 2014-04-01
SMT201600055B (it) 2016-04-29
JP5300033B2 (ja) 2013-09-25
AU2010231630A1 (en) 2011-11-10
HUE026742T2 (en) 2016-07-28
AU2010231630B2 (en) 2015-02-12
CA2757291A1 (en) 2010-10-07
KR101681347B1 (ko) 2016-11-30
CY1117193T1 (el) 2017-04-05
EP2415763A4 (en) 2012-08-15
JP5556924B2 (ja) 2014-07-23
CN102448940B (zh) 2015-10-21
CN102448940A (zh) 2012-05-09
PL2415763T3 (pl) 2016-05-31

Similar Documents

Publication Publication Date Title
AR114164A1 (es) Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
CY1117193T1 (el) Φαρμακευτικη συνθεση για θεραπεια ή αποτροπη γλαυκωματος
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
AR050952A1 (es) Derivados de indazolona; procesos para su obtencion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta - hsd1.
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
PE20090556A1 (es) DERIVADOS DE 6-CICLOAMINO-3-(PIRIDIN-4-IL) IMIDAZO [1,2-b]-PIRIDAZINA COMO INHIBIDORES DE CASEINA QUINASAS Y SU PREPARACION
PE20160540A1 (es) Inhibidores de bromodominios
PE20141110A1 (es) Derivados heterociclicos novedosos para el tratamiento de trastornos neurologicos
NI201000145A (es) DERIVADOS DE IMIDAZO - [1, 2-b] - PIRIDAZINA PARA EL TRATAMIENTO DE ENFERMEDAD MEDIADA POR CINASA DE TIROSINA C-MET.
AR089781A1 (es) Fluorometil-5,6-dihidro-4h-[1,3]oxazinas
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
MX394082B (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de cinasa pim.
AR070395A1 (es) Derivados de 4,5-dihidro-oxazol-2-il- amina
TN2014000062A1 (en) 2 -amino-4 - (pyridin- 2 -yl) - 5, 6 -dihydro-4h- 1, 3 -oxazine derivatives and their use as bace-1 and/or bace - 2 inhibitors
PE20170003A1 (es) Compuestos heterociclicos y usos de los mismos
MX2017014584A (es) Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
MX2012002179A (es) Compuestos heterociclicos de oxima.
EP2864338A2 (en) 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
UY36207A (es) Inhibidores de la syk
PE20190968A1 (es) Compuestos de heterociclo tetraciclicos utiles como inhibidores de la integrasa del vih
ATE473221T1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5- carbonsäurederivate zur behandlung von diabetes mellitus
PE20151509A1 (es) Derivado de piridina monociclico
ECSP088963A (es) Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmacéuticas que las comprenden